| abstract |
The present application relates to a pharmaceutical composition for oral administration, comprising a monoclonal antibody to tumor necrosis factor alpha (TNFα) and at least one or more pharmaceutically acceptable excipients selected from the group consisting of: a carboxymethyl-dextran, a chitosan, a cyclodextrin or a combination thereof, as well as the use of this composition in the treatment of inflammatory diseases or autoimmune diseases. |